HIGHLIGHTS
- who: BioNTech). and collaborators from the Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK have published the research: Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales, in the Journal: (JOURNAL) of 30/06/2021
- what: The aim of this study was to investigate waning in VE/relative VE (rVE) against severe COVID-19 outcomes using pooled data from across the four nations of the UK using a target trial approach . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.